198006 Comparative Outcomes of Chinese and Western Medicine Treatments among Patients with Diabetes Mellitus in Taiwan

Sunday, November 8, 2009

Brad Sheng-Chih Yen , China Medical University, Taichung 40402, Taiwan
Jaung-Geng Lin , China Medical University, Taichung 40402, Taiwan
Tsai-Chung Li , Graduate Institute of Biostatistics, China Medical University, Taichung, Taiwan
Although substantial patients with diabetes mellitus accept both Chinese and Western medicine treatments in Taiwan, there is little evidence that receiving this integrative manner can improve their conditions. Using data from the Bureau of National Health Insurance of Taiwan, we assessed the effects of receiving conventional care (Western medicine treatment only) and integrative care (both Chinese and Western medicine treatments) on patients with diabetes mellitus among 9,973 subjects 20-70 years of age during one-year follow-up. To determine which medical care improved the glucose metabolism most, HbA1c was regarded as the main indicator. Compared with their HbA1c, patients both in two different groups reduced the value with a significant result (p >.05); however, whether patients were given conventional or integrative care shows no statistical significance (p >.05). Other variables, such as comorbidity, complications, and risk factors, also influenced which medical care patients chose and the outcome of HbA1c reduction. We conclude that different medical treatments do not affect the outcome they incur, but are intervened by other variables.

Learning Objectives:
1. compare the effect of both Chinese and Western medicince treatments on Diabetes Mellitus. 2. demonstrate the results of HbA1c reduction using two treatments. 3. develop a program for taking care of patients whose annual income range from 20,000 to 30,000.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Chinese medicine biostatistics
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.